Pricing Log in Create free account

Intellia Therapeutics, Inc. (NTLA) vs Ultragenyx Pharmaceutical Inc. (RARE)

Intellia Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc. are both Biotechnology companies. Intellia Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc. are of similar size ($1.6B and $1.5B). Ultragenyx Pharmaceutical Inc. grew revenue faster over the last twelve months: 15.8% against −8.07%. Ultragenyx Pharmaceutical Inc. has the higher net margin (−71.8% vs −805.8%) and the higher return on invested capital (0.00% vs −195.3%). Across the 16 metrics below, Ultragenyx Pharmaceutical Inc. leads on 10 and Intellia Therapeutics, Inc. on 6.

Valuation

Metric NTLA RARE Biotechnology median
P/E n/m n/m 10.60
P/S 29.87 2.17 9.40
P/B 2.58 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 20.91 1.80 9.02
Earnings yield (29.72%) (33.48%) (32.88%)
Free cash flow yield (22.60%) (28.26%) (23.13%)

Profitability

Metric NTLA RARE Biotechnology median
Gross margin 100.00% 82.88% 68.51%
Operating margin (821.24%) (63.97%) 0.00%
Net margin (805.75%) (71.78%) 0.00%
Free cash flow margin (671.57%) (61.23%) 0.00%
Return on equity (62.60%) 285.68% (51.96%)
Return on assets (46.63%) (44.08%) (46.06%)
Return on invested capital (195.32%) 0.00% 0.00%

Growth

Metric NTLA RARE Biotechnology median
Revenue growth (TTM) (8.07%) 15.75% 6.76%
EPS growth (last fiscal year) 27.43% 7.31% 29.88%
Revenue growth, 5-year CAGR 3.13% 19.95% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NTLA RARE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.31 1.40 4.97
Net debt to EBITDA 1.06 1.35 1.01

Dividend

Metric NTLA RARE Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric NTLA RARE Biotechnology median
Market cap 1.56b 1.54b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack